Seres Therapeutics (MCRB) Misses Q2 EPS by 16c

Seres Therapeutics (NASDAQ: MCRB) reported Q2 EPS of ($0.53), $0.16 worse than the analyst estimate of ($0.37). Revenue for the quarter came in at $5.26 million versus the consensus estimate of $5.34 million.

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

You May Also Be Interested In

• H.C. Wainwright Starts Seres Therapeutics (MCRB) at Buy
• Morgan Stanley Starts Adani Enterprises Ltd. (ADE:IN) at Overweight
• Morgan Stanley upgrades CDW on stronger AI-driven server demand